Wockhardt's Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Total investment incurred for setting up the new R&D Rs 250 crore
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
The acquisition is based on an enterprise value of Rs. 1,660 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Subscribe To Our Newsletter & Stay Updated